BRKR vs. BIO, AVTR, TXG, WAT, PACB, QTRX, AXDX, MTD, A, and ZG
Should you be buying Bruker stock or one of its competitors? The main competitors of Bruker include Bio-Rad Laboratories (BIO), Avantor (AVTR), 10x Genomics (TXG), Waters (WAT), Pacific Biosciences of California (PACB), Quanterix (QTRX), Accelerate Diagnostics (AXDX), Mettler-Toledo International (MTD), Agilent Technologies (A), and Zillow Group (ZG).
Bruker (NASDAQ:BRKR) and Bio-Rad Laboratories (NYSE:BIO) are both computer and technology companies, but which is the better business? We will compare the two companies based on the strength of their community ranking, valuation, media sentiment, dividends, analyst recommendations, risk, earnings, profitability and institutional ownership.
Bruker has a net margin of 14.41% compared to Bio-Rad Laboratories' net margin of -23.86%. Bruker's return on equity of 29.94% beat Bio-Rad Laboratories' return on equity.
Bruker received 306 more outperform votes than Bio-Rad Laboratories when rated by MarketBeat users. However, 65.10% of users gave Bio-Rad Laboratories an outperform vote while only 64.98% of users gave Bruker an outperform vote.
Bruker has higher revenue and earnings than Bio-Rad Laboratories. Bio-Rad Laboratories is trading at a lower price-to-earnings ratio than Bruker, indicating that it is currently the more affordable of the two stocks.
79.8% of Bruker shares are held by institutional investors. Comparatively, 64.0% of Bio-Rad Laboratories shares are held by institutional investors. 28.2% of Bruker shares are held by insiders. Comparatively, 17.1% of Bio-Rad Laboratories shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.
In the previous week, Bio-Rad Laboratories had 4 more articles in the media than Bruker. MarketBeat recorded 12 mentions for Bio-Rad Laboratories and 8 mentions for Bruker. Bruker's average media sentiment score of 1.06 beat Bio-Rad Laboratories' score of 0.51 indicating that Bruker is being referred to more favorably in the media.
Bruker has a beta of 1.17, suggesting that its stock price is 17% more volatile than the S&P 500. Comparatively, Bio-Rad Laboratories has a beta of 0.87, suggesting that its stock price is 13% less volatile than the S&P 500.
Bruker presently has a consensus price target of $84.29, suggesting a potential downside of 8.41%. Bio-Rad Laboratories has a consensus price target of $493.75, suggesting a potential upside of 48.08%. Given Bio-Rad Laboratories' stronger consensus rating and higher probable upside, analysts clearly believe Bio-Rad Laboratories is more favorable than Bruker.
Summary
Bruker beats Bio-Rad Laboratories on 13 of the 17 factors compared between the two stocks.
Get Bruker News Delivered to You Automatically
Sign up to receive the latest news and ratings for BRKR and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding BRKR and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip ChartThis chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart
Related Companies and Tools